Drug Discovery
By
PhaseV Reports Breakthrough Year in 2025, Marking Transition to Scaled AI Deployment in Clinical Development
Boston, Massachusetts PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue…
Takeda Announces Positive Phase III Results for AI-Discovered Oral Psoriasis Therapy
Tokyo, Japan – December 19, 2025 – Takeda Pharmaceutical Company Limited today announced successful results from two Phase…
Cradle AI-powered protein engineering platform serving six of the top 25 global pharma leaders
AMSTERDAM and ZURICH, Dec. 16, 2025 — Cradle, an enterprise-grade AI software platform for protein engineering, today announced…
Adaptive Biotechnologies and Pfizer Announce Strategic Research Collaboration Valued Up to $890 Million to Advance Breakthrough Therapies for Rheumatoid Arthritis and Immune-Mediated Diseases
A target discovery agreement to identify disease-specific T-cell receptors (TCRs) in rheumatoid arthritis. A data licensing agreement to…
Has the FDA Approval of Breyanzi Expanded CAR T Cell Therapy Options for Marginal Zone Lymphoma Patients?
Bristol Myers Squibb has received approval from the U.S. Food and Drug Administration for Breyanzi, a CD19-directed CAR…
Does a New Kidney Cancer Trial Expand Long-Term Oncology Optionality for Bristol-Myers Squibb and BioNTech?
December 2025 — Bristol-Myers Squibb and BioNTech have announced progress in their oncology collaboration with the initiation of…
